If you have a 4K UHD TV, you'll never see higher quality picture, and if you have a pile of old DVDs, you'll never see them look better, either.

Y: Marshals will see Kayce Dutton using his military training to “bring range justice to Montana, where he and his teammates ...

Sanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of ...

Sanofi SA is to acquire Blueprint Medicines Inc. in a $9.5 billion deal that will give the French pharma ownership of a marketed rare disease immunotherapy heading toward blockbuster status, a ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 ...

Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.

Sanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Biotech takeover brings a breakout drug, bold immunology bets, and one mystery molecule that could reshape inflammation ...